新型抗血栓药物用于COVID-19:正在进行的随机对照试验系统总结
该研究系统检索了clinicaltrials.gov和WHO ICTRP,识别出27项评估10种新型抗血栓药物(包括nafamostat、dociparstat、rNAPc2和defibrotide)用于COVID-19患者的RCT,结果尚未公布。这些药物涉及凝血级联、内皮活化及混合作用机制,部分具有多效抗炎和抗病毒效应,可能减少病毒载量或纤维化并改善氧合。
要点
- 共识别27项RCT,评估10种新型抗血栓药物用于COVID-19患者。
- 药物机制涵盖凝血级联、内皮活化及混合作用,部分兼具抗炎和抗病毒效应。
- 所有试验结果尚未公布,实际临床角色待RCT结果阐明。
核心结论
- 部分新型抗血栓药物具有多效抗炎和抗病毒效应,可能有助于减少病毒载量或纤维化并改善氧合。
- 正在进行的RCT结果将阐明这些药物在COVID-19患者管理中的实际作用。
研究设计与样本
- 系统检索clinicaltrials.gov和WHO国际临床试验注册平台,识别COVID-19患者中新型抗血栓药物的RCT。
主要发现
- 共识别27项RCT,涉及10种新型抗血栓药物,包括nafamostat、dociparstat、rNAPc2和defibrotide。
- 这些试验的结果尚未传播公布。
- 研究中药物包括影响凝血级联的药物、影响内皮活化的药物及混合作用药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with macro- and micro-thromboses, which are triggered by endothelial cell activation, coagulopathy, and uncontrolled inflammatory response. Conventional antithrombotic agents are under assessment in dozens of randomized controlled trials (RCTs) in patients with COVID-19, with preliminary results not demonstrating benefit in several studies. OBJECTIVES: Given the possibility that more novel agents with antithrombotic effects may have a potential utility for management of patients with COVID-19, we assessed ongoing RCTs including these agents with their potential mechanism of action in this population. METHODS: We searched clinicaltrials.gov and the World Health Organization International Clinical Trials Registry Platform to identify RCTs of novel antithrombotic agents in patients with COVID-19. RESULTS: Based on a systematic literature search, 27 RCTs with 10 novel antithrombotic agents (including nafamostat, dociparstat, rNAPc2, and defibrotide) were identified. The results from these trials have not been disseminated yet. The studied drugs in the ongoing or completed RCTs include agents affecting the coagulation cascade, drugs affecting endothelial activation, and mixed acting agents. Their postulated antithrombotic mechanisms of action and their potential impact on patient management are summarized. CONCLUSION: Some novel antithrombotic agents have pleiotropic anti-inflammatory and antiviral effects, which may help reduce the viral load or fibrosis, and improve oxygenation. Results from ongoing RCTs will elucidate their actual role in the management of patients with COVID-19.
引用
- Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, et al. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost. 2021. PMID: 34538017. doi:10.1111/jth.15533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。